Kardium has raised a sizeable round of financing, the Vancouver-based medical solutions company announced this week.
The Canadian innovator confirmed US$250 million in an oversubscribed round led by investors Janus Henderson Investors, Qatar Investment Authority , MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors also participated.
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors,” stated Kevin Chaplin, chief executive officer of Kardium.
Kardium is known for its development of the Globe System, which features a sophisticated device with a 122-electrode array and advanced software that enables rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium–all with a single catheter.
Atrial fibrillation is an electrical disorder of the upper chambers of the heart that can cause rapid electrical signals that interfere with the ability of the chambers to contract in a coordinated way, which can cause decreased pumping action and passive blood flow in the heart.
Kardium is a member of the BC Tech Association.
BC Tech is the largest member-led technology non-profit in British Columbia, and we’re dedicated to turning startups and scaleups into the anchor companies of tomorrow. Our work supports members to grow and diversify their talent pool, acquire new customers, access capital and accelerate their scaleup journey. Technology is a key industry for BC’s future and builds resiliency in every industry. Today, every company is a tech company. Join\ now.
Based on more than a decade of research and development and more than 100 patents, Kardium’s Globe PF Mapping and Ablation System is the only system to combine rapid PV isolation, high-resolution mapping, and atrial ablation into a complete solution, according to Chaplin, who says this latest round of funding “enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team.”
The capital also empowers Kardium to pursue regulatory approvals for the Globe System and establish clinical support in preparation for the commercial launch of the product, which Chaplin suggests could be as soon as later this year.
“Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation,” he said.
Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors, describes the Globe System as “a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation.”
Clinical data from the PULSAR clinical study of the Globe System was recently presented at the 2025 Heart Rhythm Society annual meeting. Results showed freedom from atrial arrhythmia at one year of 78% in paroxysmal AF patients.
“This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardium’s groundbreaking technology to the market,” Schaechterle stated.
Founded in 2007, Kardium raised US$115M in 2021 and another $143M in 2024.
Leave a Reply